

What is claimed is:

1. A compound selected from the group consisting of:
  - 4-[Amino-(3,5-bis-trifluoromethyl-phenyl)-methyl]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;
  - (2R, 4R, 4aS)-4-[Amino-(3,5-bis-trifluoromethyl-phenyl)-methyl]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;
  - (2R, 4S, 4aS)-4-[Amino-(3,5-bis-trifluoromethyl-phenyl)-methyl]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;
  - 4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid *n*-propyl ester;
  - (2R, 4R, 4aS)-4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid *n*-propyl ester;
  - (2R, 4S, 4aS)-4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid *n*-propyl ester;
  - 4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isobutyl ester;
  - (2R, 4R, 4aS)-4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isobutyl ester;
  - (2R, 4S, 4aS)-4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isobutyl ester;
  - 4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl)-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;
  - (2S, 4R, 4aS)-4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl)-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;
  - (2S, 4S, 4aS)-4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl)-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;
  - 4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl)-2-methyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;
  - (2R, 4R, 4aS)-4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl)-2-methyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;
  - (2R, 4S, 4aS)-4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl)-2-methyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;
  - 4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl)-2-methyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;
  - (2R, 4R, 4aS)-4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl)-2-methyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;
  - (2R, 4S, 4aS)-4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl)-2-methyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;
  - 4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl)-2-methyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid *n*-propyl ester;

(2*R*, 4*R*, 4*aS*)- 4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl)-2-methyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid *n*-propyl ester;

(2*R*, 4*S*, 4*aS*)- 4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl)-2-methyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid *n*-propyl ester;

4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl)-2-methyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid *t*-butyl ester;

(2*R*, 4*R*, 4*aS*)- 4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl)-2-methyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid *t*-butyl ester;

(2*R*, 4*S*, 4*aS*)- 4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl)-2-methyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid *t*-butyl ester;

4-[Amino-(3,5-bis(chloro-phenyl)-methyl)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid ethyl ester;

(2*R*, 4*R*, 4*aS*)- 4-[Amino-(3,5-bis(chloro-phenyl)-methyl)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid ethyl ester;

(2*R*, 4*S*, 4*aS*)- 4-[Amino-(3,5-bis(chloro-phenyl)-methyl)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid ethyl ester;

4-[Amino-(3-chloro-5-trifluoromethyl-phenyl)-methyl)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid ethyl ester;

(2*R*, 4*R*, 4*aS*)- 4-[Amino-(3-chloro-5-trifluoromethyl-phenyl)-methyl)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid ethyl ester;

(2*R*, 4*S*, 4*aS*)- 4-[Amino-(3-chloro-5-trifluoromethyl-phenyl)-methyl)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid ethyl ester; and

or a pharmaceutically acceptable salt of said compound.

2. A compound according to claim 1 selected from the group consisting of:

4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid isopropyl ester;

4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid *n*-propyl ester;

4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid isobutyl ester;

4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl)-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid isopropyl ester;

4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl)-2-methyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid ethyl ester;

4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl)-2-methyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid isopropyl ester;

4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl)-2-methyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid *n*-propyl ester;

4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl)-2-methyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid *t*-butyl ester;

4-[Amino-(3,5-bis(chloro-phenyl)-methyl)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid ethyl ester;

4-[Amino-(3-chloro-5-trifluoromethyl-phenyl)-methyl]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid ethyl ester;

or a pharmaceutically acceptable salt of said compound.

3. A compound according to claim 1 selected from the group consisting of:

(2*R*, 4*R*, 4*aS*)-4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid isopropyl ester;

(2*R*, 4*R*, 4*aS*)-4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid *n*-propyl ester;

(2*R*, 4*R*, 4*aS*)-4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid isobutyl ester;

(2*S*, 4*R*, 4*aS*)-4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl)-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid isopropyl ester;

(2*R*, 4*R*, 4*aS*)-4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl)-2-methyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid ethyl ester;

(2*R*, 4*R*, 4*aS*)-4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl)-2-methyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid isopropyl ester;

(2*R*, 4*R*, 4*aS*)-4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl)-2-methyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid *n*-propyl ester;

(2*R*, 4*R*, 4*aS*)-4-[Amino-(3,5-bis(trifluoromethyl-phenyl)-methyl)-2-methyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid *t*-butyl ester;

(2*R*, 4*R*, 4*aS*)-4-[Amino-(3,5-bis(chloro-phenyl)-methyl)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid ethyl ester;

(2*R*, 4*R*, 4*aS*)-4-[Amino-(3-chloro-5-trifluoromethyl-phenyl)-methyl]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2*H*-quinoline-1-carboxylic acid ethyl ester;

or a pharmaceutically acceptable salt of said compound.

4. A method for treating atherosclerosis, coronary artery disease, coronary heart disease, coronary vascular disease, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial-hypercholesterolemia or myocardial infarction in a mammal by administering to a mammal in need of such treatment an atherosclerosis, coronary artery disease, coronary heart disease, coronary vascular disease, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial-hypercholesterolemia or myocardial infarction treating amount of a compound of claim 1 or a pharmaceutically acceptable salt of said compound.

5. A pharmaceutical composition which comprises a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt of said compound and a pharmaceutically acceptable vehicle, diluent or carrier.

6. A pharmaceutical composition for the treatment of atherosclerosis, coronary artery disease, coronary heart disease, coronary vascular disease, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia,

familial-hypercholesterolemia or myocardial infarction in a mammal which comprises a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt of said compound and a pharmaceutically acceptable vehicle, diluent or carrier.

7. A pharmaceutical combination composition comprising: a therapeutically effective amount of a composition comprising

a first compound, said first compound being a compound of claim 1 or a pharmaceutically acceptable salt of said compound;

a second compound, said second compound being an HMG CoA reductase inhibitor, an MTP/Apo B secretion inhibitor, a PPAR modulator, a bile acid reuptake inhibitor, a cholesterol absorption inhibitor, a cholesterol synthesis inhibitor, a fibrate, niacin, slow-release niacin, a combination of niacin and lovastatin, an ion-exchange resin, an antioxidant, an ACAT inhibitor or a bile acid sequestrant; and  
a pharmaceutical vehicle, diluent or carrier.

8. A pharmaceutical combination composition as recited in claim 7 wherein the second compound is an HMG-CoA reductase inhibitor or a PPAR modulator.

9. A pharmaceutical combination composition as recited in claim 8 wherein the second compound is lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rivastatin, rosuvastatin or pitavastatin.

10. A method for treating atherosclerosis in a mammal comprising administering to a mammal in need of treatment thereof;

a first compound, said first compound being a compound of claim 1 or a pharmaceutically acceptable salt of said compound; and

a second compound, said second compound being an HMG CoA reductase inhibitor, a PPAR modulator, a cholesterol absorption inhibitor, a cholesterol synthesis inhibitor, a fibrate, niacin, slow-release niacin, a combination of niacin and lovastatin, an ion-exchange resin, an antioxidant, an ACAT inhibitor or a bile acid sequestrant

wherein the amounts of first and second compounds result in a therapeutic effect.

11. A method for treating atherosclerosis as recited in claim 10 wherein the second compound is an HMG-CoA reductase inhibitor or a PPAR modulator.

12. A method for treating atherosclerosis as recited in claim 11 wherein the second compound is lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rivastatin, rosuvastatin or pitavastatin.

13. A kit for achieving a therapeutic effect in a mammal comprising packaged in association a first therapeutic agent comprising a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt of said compound and a pharmaceutically acceptable carrier, a second therapeutic agent comprising a therapeutically effective amount of an HMG CoA reductase inhibitor, a PPAR modulator, a cholesterol absorption inhibitor, a cholesterol synthesis inhibitor, a fibrate, niacin, slow-release niacin, a combination of niacin and lovastatin, an ion-exchange resin, an antioxidant, an ACAT inhibitor or a bile acid sequestrant and a pharmaceutically acceptable carrier and directions for administration of said first and second agents to achieve the therapeutic effect.

14. A kit as recited in claim 13 wherein said second therapeutic agent comprises an HMG-CoA reductase inhibitor or a PPAR modulator.

15. A kit as recited in claim 14 wherein said second therapeutic agent comprises lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rivastatin, rosuvastatin or pitavastatin.